NCT04177316

Brief Summary

The clinic-pathological data were retrieved from the cancer registry database from the Cancer Center of Chang Gung Memorial Hospital, Linkou branch. Of the 92 HCC patients with partial hepatectomies enrolled. The biological specimen was studied with approval.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
92

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Dec 2018

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2018

Completed
12 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 15, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 15, 2019

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

November 22, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 26, 2019

Completed
Last Updated

November 26, 2019

Status Verified

November 1, 2019

Enrollment Period

12 months

First QC Date

November 22, 2019

Last Update Submit

November 24, 2019

Conditions

Hepatocellular Carcinoma Resectable

Keywords

VTRNA2-1 promoterrecurrencemethylation

Outcome Measures

Primary Outcomes (1)

  • disease free survival (DFS)

    The length of time from curative hepatectomies treatment and recurrence or mortality

    a month

Secondary Outcomes (1)

  • Overall survival

    a month

Study Arms (2)

hypermethylation

The hypermethylation group was defined as differential methylation status of tumor- normal ≥ 5%.

hypomethylation/no change

The hypomethylation were defined as differential methylation status of tumor- normal \<5%

Eligibility Criteria

Age20 Years - 85 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

HCC patients with curative partial hepatectomies and the pathology reports proved.

You may qualify if:

  • subjects with pathologic diagnosis of hepatocellular carcinoma curative partial hepatectomies

You may not qualify if:

  • history of different malignant disease. subjects cannot be treated with curative surgery.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ming-Chin Yu

Taoyuan District, 333, Taiwan

Location

Biospecimen

Retention: SAMPLES WITH DNA

frozen specimen of tumor and normal parts at Central Biobank of Chang Gung Memorial Hospital

MeSH Terms

Conditions

Recurrence

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Ming-Chin Yu, MD, PhD

    Chang Gung Memorial Hospital

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 22, 2019

First Posted

November 26, 2019

Study Start

December 1, 2018

Primary Completion

November 15, 2019

Study Completion

November 15, 2019

Last Updated

November 26, 2019

Record last verified: 2019-11

Data Sharing

IPD Sharing
Will not share

Locations

TW(1)